MediGene to Present at the Rodman & Renshaw Healthcare Conference

Internet live webcast on November 06, 2007 available at www.medigene.com Martinsried/Munich, November 30, 2007. Today, the biotech company MediGene (Frankfurt, Prime Standard: MDG) announced that the company will be presenting at The Rodman & Renshaw Healthcare Conference, on November 06, 2007 at 12:20 a.m. (18:20 MEST) in New York. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on current business developments. The presentation will be available on the internet at www.medigene.com from October 06, 2007 on. MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard® for the treatment of prostate cancer). A second drug (Polyphenon® E Ointment for the treatment of genital warts) has been approved by the FDA, the MAA for a third drug, Oracea® for the treatment of rosacea is under review in several European countries. Several other drug candidates are in clinical development for the treatment of cancer and autoimmune therapies. In addition, MediGene owns cutting-edge platform technologies with the EndoTAG(TM), oncolytic HSV and mTCR (soluble T-cell receptor) technologies. The drug candidate EndoTAG(TM)-1 (clinical phase II in pancreatic cancer and breast cancer enrolling 200 and 135 patients, respectively) aims at "starving out" tumors by destroying the supplying blood vessels. RhuDex® is the first oral CD80 interactor and is developed for the treatment of rheumatoid arthritis. MediGene's innovative oncolytic HSV (herpes simplex viruses) (phase I/II in glioma and liver metastases) are modified for the selective destruction of tumor cells without harming healthy tissue. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. EndoTAGTM-1 and the MediGeneTM Logo are trademarks of MediGene AG, Eligard® is a trademark of Atrix Laboratories/Sanofi-Aventis, Polyphenon E® is a trademark of Mitsui Norin, Oracea® is a trademark of CollaGenex, Inc., RhuDex® is a trademark of MediGene Ltd. - ends - MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. Another drug obtained marketing authorization for the USA and is currently undergoing the European approval procedures. Furthermore MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development. Contact MediGene AG: Email: investor@medigene.com Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946 --- End of Message --- MediGene AG Lochhamer Strasse 11 Martinsried / München Germany WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;